{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:10:11Z","timestamp":1744179011311,"version":"3.40.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["EMR\/ 2016\/ 007246"],"award-info":[{"award-number":["EMR\/ 2016\/ 007246"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001849","name":"Defence Research and Development Organisation","doi-asserted-by":"publisher","award":["LSRB-297"],"award-info":[{"award-number":["LSRB-297"]}],"id":[{"id":"10.13039\/501100001849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Microbiol Biotechnol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00253-020-10541-y","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T13:03:42Z","timestamp":1585573422000},"page":"4333-4344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Production and immunogenicity of Fubc subunit protein redesigned from DENV envelope protein"],"prefix":"10.1007","volume":"104","author":[{"given":"Abhishek Singh","family":"Rathore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinkoo Devi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"10541_CR1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cmi.2018.01.018","volume":"24","author":"JL Arredondo-Garc\u00eda","year":"2018","unstructured":"Arredondo-Garc\u00eda JL, Hadinegoro SR, Reynales H, Chua MN, Rivera Medina DM, Chotpitayasunondh T, Zambrano B (2018) Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect 24:755\u2013763. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.018","journal-title":"Clin Microbiol Infect"},{"key":"10541_CR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GRW, Simmons CP, Scott TW, Farrar JJ, Hay SI (2013) The global distribution and burden of dengue. Nature 496:504\u2013507. https:\/\/doi.org\/10.1038\/nature12060","journal-title":"Nature"},{"key":"10541_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001760","volume":"6","author":"OJ Brady","year":"2012","unstructured":"Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI (2012) Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 6:e1760. https:\/\/doi.org\/10.1371\/journal.pntd.0001760","journal-title":"PLoS Negl Trop Dis"},{"key":"10541_CR4","doi-asserted-by":"publisher","unstructured":"Casta\u00f1o-Osorio JC, Giraldo-Garcia AM, Giraldo MI. (2019) Current status of vaccines against dengue virus. Dengue fever - a resilient threat in the face of innovation IntechOpen Book chapter 9. https:\/\/doi.org\/10.5772\/intechopen.80820","DOI":"10.5772\/intechopen.80820"},{"key":"10541_CR5","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1038\/emboj.2009.245","volume":"28","author":"MV Cherrier","year":"2009","unstructured":"Cherrier MV, Kaufmann B, Nybakken GE, Lok S-M, Warren JT, Chen BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG, Fremont DH (2009) Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J 28:3269\u20133276. https:\/\/doi.org\/10.1038\/emboj.2009.245","journal-title":"EMBO J"},{"key":"10541_CR6","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.1016\/j.vaccine.2011.07.021","volume":"29","author":"B-AG Coller","year":"2011","unstructured":"Coller B-AG, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH (2011) The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29:7267\u20137275. https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.021","journal-title":"Vaccine"},{"key":"10541_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1128\/JVI.02273-12","volume":"87","author":"JM Costin","year":"2013","unstructured":"Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang S-T, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, Michael SF, Schieffelin JS, Isern S (2013) Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol 87:52\u201366. https:\/\/doi.org\/10.1128\/JVI.02273-12","journal-title":"J Virol"},{"key":"10541_CR8","doi-asserted-by":"publisher","first-page":"7261","DOI":"10.1016\/j.vaccine.2011.07.019","volume":"29","author":"JR Danko","year":"2011","unstructured":"Danko JR, Beckett CG, Porter KR (2011) Development of dengue DNA vaccines. Vaccine 29:7261\u20137266. https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.019","journal-title":"Vaccine"},{"key":"10541_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","volume":"98","author":"JR Danko","year":"2018","unstructured":"Danko JR, Kochel T, Teneza-Mora N, Luke TC, Raviprakash K, Sun P, Porter KR (2018) Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial. Am J Trop Med Hyg 98:849\u2013856. https:\/\/doi.org\/10.4269\/ajtmh.17-0416","journal-title":"Am J Trop Med Hyg"},{"key":"10541_CR10","doi-asserted-by":"publisher","first-page":"e1004386","DOI":"10.1371\/journal.ppat.1004386","volume":"10","author":"R De Alwis","year":"2014","unstructured":"De Alwis R, Williams KL, Schmid MA, Lai C-Y, Patel B, Smith SA, Crowe JE, Wang W-K, Harris E, de Silva AM (2014) Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog 10:e1004386. https:\/\/doi.org\/10.1371\/journal.ppat.1004386","journal-title":"PLoS Pathog"},{"key":"10541_CR11","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4269\/ajtmh.17-0627","volume":"98","author":"C Diaz","year":"2018","unstructured":"Diaz C, Lin L, Martinez LJ, Eckels KH, Campos M, Jarman RG, De La Barrera R, Lepine E, Toussaint JF, Febo I, Innis BL, Thomas SJ, Schmidt AC (2018) Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico. Am J Trop Med Hyg 98:1435\u20131443. https:\/\/doi.org\/10.4269\/ajtmh.17-0627","journal-title":"Am J Trop Med Hyg"},{"key":"10541_CR12","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","volume":"29","author":"AP Durbin","year":"2011","unstructured":"Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS (2011) Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29:7242\u20137250. https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.023","journal-title":"Vaccine"},{"key":"10541_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.aaa8651","volume":"349","author":"G Fibriansah","year":"2015","unstructured":"Fibriansah G, Ibarra KD, Ng TS, Smith SA, Tan JL, Lim XN, Ooi JS, Kostyuchenko VA, Wang J, de Silva AM, Harris E, Crowe JE, Lok SM (2015) Dengue virus cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349:88\u201391. https:\/\/doi.org\/10.1126\/science.aaa8651","journal-title":"Science"},{"key":"10541_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.antiviral.2016.01.002","volume":"128","author":"G Fibriansah","year":"2016","unstructured":"Fibriansah G, Lok SM (2016) The development of therapeutic antibodies against dengue virus. Antivir Res 128:7\u201319. https:\/\/doi.org\/10.1016\/j.antiviral.2016.01.002","journal-title":"Antivir Res"},{"key":"10541_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/tra.12012","volume":"14","author":"J Flipse","year":"2013","unstructured":"Flipse J, Wilschut J, Smit JM (2013) Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic 14:25\u201335. https:\/\/doi.org\/10.1111\/tra.12012","journal-title":"Traffic"},{"key":"10541_CR16","doi-asserted-by":"publisher","unstructured":"Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Baric, RS 2015 A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio 6. https:\/\/doi.org\/10.1128\/mbio.01461-15","DOI":"10.1128\/mbio.01461-15"},{"key":"10541_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pervac.2011.05.004","volume":"1","author":"N Gar\u00e7on","year":"2011","unstructured":"Gar\u00e7on N, Leroux-Roels G, Cheng W-F (2011) Vaccine adjuvants. Persp Vaccinol 1:89\u2013113. https:\/\/doi.org\/10.1016\/j.pervac.2011.05.004","journal-title":"Persp Vaccinol"},{"key":"10541_CR18","doi-asserted-by":"publisher","unstructured":"Giraldo-Garc\u00eda AM, Casta\u00f1o-Osorio JC (2019) Development of a dengue vaccine and its use in pregnant women. Curr Trop Med Rep. https:\/\/doi.org\/10.1007\/s40475-019-00192","DOI":"10.1007\/s40475-019-00192"},{"key":"10541_CR19","doi-asserted-by":"publisher","first-page":"9422","DOI":"10.1073\/pnas.0703498104","volume":"104","author":"AP Goncalvez","year":"2007","unstructured":"Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai C-J (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104:9422\u20139427. https:\/\/doi.org\/10.1073\/pnas.0703498104","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10541_CR20","doi-asserted-by":"publisher","first-page":"12919","DOI":"10.1128\/JVI.78.23.12919-12928.2004","volume":"78","author":"AP Goncalvez","year":"2004","unstructured":"Goncalvez AP, Purcell RH, Lai C-J (2004) Epitope determinants of a chimpanzee fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol 78:12919\u201312928. https:\/\/doi.org\/10.1128\/JVI.78.23.12919-12928.2004","journal-title":"J Virol"},{"key":"10541_CR21","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1016\/j.vaccine.2015.06.067","volume":"33","author":"D Govindarajan","year":"2015","unstructured":"Govindarajan D, Meschino S, Guan L, Clements DE, ter Meulen JH, Casimiro DR, Coller B-AG, Bett AJ (2015) Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates. Vaccine 33:4105\u20134116. https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.067","journal-title":"Vaccine"},{"key":"10541_CR22","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","volume":"29","author":"B Guy","year":"2011","unstructured":"Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J (2011) From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29:7229\u20137241. https:\/\/doi.org\/10.1016\/j.vaccine.2011.06.094","journal-title":"Vaccine"},{"key":"10541_CR23","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1016\/j.vaccine.2015.09.108","volume":"33","author":"B Guy","year":"2015","unstructured":"Guy B, Briand O, Lang J, Saville M, Jackson N (2015) Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine 33:7100\u20137111. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.108","journal-title":"Vaccine"},{"key":"10541_CR24","doi-asserted-by":"publisher","first-page":"16055","DOI":"10.1038\/nrdp.2016.55","volume":"2","author":"MG Guzman","year":"2016","unstructured":"Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB (2016) Dengue infection. Nat Rev Dis Primers 2:16055. https:\/\/doi.org\/10.1038\/nrdp.2016.55","journal-title":"Nat Rev Dis Primers"},{"key":"10541_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1586\/erv.09.139","volume":"9","author":"MG Guzman","year":"2010","unstructured":"Guzman MG, Hermida L, Bernardo L, Ramirez R, Guill\u00e9n G (2010) Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 9:137\u2013147. https:\/\/doi.org\/10.1586\/erv.09.139","journal-title":"Expert Rev Vaccines"},{"key":"10541_CR26","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1016\/j.vaccine.2006.01.036","volume":"24","author":"L Hermida","year":"2006","unstructured":"Hermida L, Bernardo L, Mart\u00edn J, Alvarez M, Prado I, L\u00f3pez C, de la C Sierra B, Mart\u00ednez R, Rodr\u00edguez R, Zulueta A, P\u00e9rez AB, Lazo L, Rosario D, Guill\u00e9n G, Guzm\u00e1n MG (2006) A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24:3165\u20133171. https:\/\/doi.org\/10.1016\/j.vaccine.2006.01.036","journal-title":"Vaccine"},{"key":"10541_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1586\/14760584.6.5.747","volume":"6","author":"D Higgins","year":"2007","unstructured":"Higgins D, Marshall JD, Traquina P, Van Nest G, Livingston BD (2007) Immunostimulatory DNA as a vaccine adjuvant. Expert Rev Vaccines 6:747\u2013759. https:\/\/doi.org\/10.1586\/14760584.6.5.747","journal-title":"Expert Rev Vaccines"},{"key":"10541_CR28","doi-asserted-by":"publisher","unstructured":"Imai N, Ferguson NM (2018) Targeting vaccinations for the licensed dengue vaccine: considerations for serosurvey design. PLoS One:13. https:\/\/doi.org\/10.1371\/journal.pone.0199450","DOI":"10.1371\/journal.pone.0199450"},{"key":"10541_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbapap.2005.06.005","volume":"1751","author":"SM Kelly","year":"2005","unstructured":"Kelly SM, Jess TJ, Price NC (2005) How to study proteins by circular dichroism. Biochim Biophys Acta 1751:119\u2013139. https:\/\/doi.org\/10.1016\/j.bbapap.2005.06.005","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10541_CR30","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1128\/JVI.02957-12","volume":"87","author":"DE Klein","year":"2013","unstructured":"Klein DE, Choi JL, Harrison SC (2013) Structure of a dengue virus envelope protein late-stage fusion intermediate. J Virol 87(4):2287\u20132293. https:\/\/doi.org\/10.1128\/JVI.02957-12","journal-title":"J Virol"},{"key":"10541_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/trstmh\/tru167","volume":"109","author":"SL Klein","year":"2015","unstructured":"Klein SL, Marriott I, Fish EN (2015) Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg 109:9\u201315. https:\/\/doi.org\/10.1093\/trstmh\/tru167","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10541_CR32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0092-8674(02)00660-8","volume":"108","author":"RJ Kuhn","year":"2002","unstructured":"Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717\u2013725","journal-title":"Cell"},{"key":"10541_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s12551-017-0314-2","volume":"9","author":"PS Kumagai","year":"2017","unstructured":"Kumagai PS, Araujo APU, Lopes JLS (2017) Going deep into protein secondary structure with synchrotron radiation circular dichroism spectroscopy. Biophys Rev 9:517\u2013527. https:\/\/doi.org\/10.1007\/s12551-017-0314-2","journal-title":"Biophys Rev"},{"key":"10541_CR34","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1128\/JVI.00316-08","volume":"82","author":"C-Y Lai","year":"2008","unstructured":"Lai C-Y, Tsai W-Y, Lin S-R, Kao C-L, Hu H-P, King C-C, Wu H-C, Chang G-J, Wang W-K (2008) Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82:6631\u20136643. https:\/\/doi.org\/10.1128\/JVI.00316-08","journal-title":"J Virol"},{"key":"10541_CR35","doi-asserted-by":"publisher","first-page":"e1007716","DOI":"10.1371\/journal.ppat.1007716","volume":"15","author":"L Li","year":"2019","unstructured":"Li L, Meng W, Horton M, DiStefano DR, Thoryk EA, Pfaff JM, Wang Q, Salazar GT, Barnes T, Doranz BJ, Bett AJ, Casimiro DR, Vora KA, An Z, Zhang N (2019) Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes. PLoS Pathog 15:e1007716. https:\/\/doi.org\/10.1371\/journal.ppat.1007716","journal-title":"PLoS Pathog"},{"key":"10541_CR36","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1128\/CVI.00770-14","volume":"22","author":"G Liu","year":"2015","unstructured":"Liu G, Song L, Beasley DWC, Putnak R, Parent J, Misczak J, Li H, Reiserova L, Liu X, Tian H, Liu W, Labonte D, Duan L, Kim Y, Travalent L, Wigington D, Weaver B, Tussey L (2015) Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys. Clin Vaccine Immunol 22:516\u2013525. https:\/\/doi.org\/10.1128\/CVI.00770-14","journal-title":"Clin Vaccine Immunol"},{"key":"10541_CR37","doi-asserted-by":"publisher","first-page":"11.4.1","DOI":"10.1002\/cpmb.30","volume":"117","author":"T Maira-Litr\u00e1n","year":"2017","unstructured":"Maira-Litr\u00e1n T (2017) Immunization of mice. Curr Protoc Mol Biol 117:11.4.1\u201311.4.11. https:\/\/doi.org\/10.1002\/cpmb.30","journal-title":"Curr Protoc Mol Biol"},{"key":"10541_CR38","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1128\/CMR.00035-09","volume":"22","author":"BEE Martina","year":"2009","unstructured":"Martina BEE, Koraka P, Osterhaus ADME (2009) Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 22:564\u2013581. https:\/\/doi.org\/10.1128\/CMR.00035-09","journal-title":"Clin Microbiol Rev"},{"key":"10541_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1039\/b316168b","volume":"35","author":"AJ Miles","year":"2006","unstructured":"Miles AJ, Wallace BA (2006) Synchrotron radiation circular dichroism spectroscopy of proteins and applications in structural and functional genomics. Chem Soc Rev 35:39\u201351. https:\/\/doi.org\/10.1039\/b316168b","journal-title":"Chem Soc Rev"},{"key":"10541_CR40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature02165","volume":"427","author":"Y Modis","year":"2004","unstructured":"Modis Y, Ogata S, Clements D, Harrison SC (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313\u2013319. https:\/\/doi.org\/10.1038\/nature02165","journal-title":"Nature"},{"key":"10541_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev-immunol-031210-101315","volume":"29","author":"BR Murphy","year":"2011","unstructured":"Murphy BR, Whitehead SS (2011) Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29:587\u2013619. https:\/\/doi.org\/10.1146\/annurev-immunol-031210-101315","journal-title":"Annu Rev Immunol"},{"key":"10541_CR42","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1128\/JVI.02574-08","volume":"83","author":"V Nayak","year":"2009","unstructured":"Nayak V, Dessau M, Kucera K, Anthony K, Ledizet M, Modis Y (2009) Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J Virol 83:4338\u20134344. https:\/\/doi.org\/10.1128\/JVI.02574-08","journal-title":"J Virol"},{"key":"10541_CR43","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S0140-6736(18)30245-9","volume":"391","author":"T Pang","year":"2018","unstructured":"Pang T, Gubler D, Goh DYT, Ismail Z (2018) Dengue vaccination: a more balanced approach is needed. Lancet 391:654. https:\/\/doi.org\/10.1016\/S0140-6736(18)30245-9","journal-title":"Lancet"},{"key":"10541_CR44","doi-asserted-by":"publisher","first-page":"e0209576","DOI":"10.1371\/journal.pone.0209576","volume":"14","author":"AS Rathore","year":"2019","unstructured":"Rathore AS, Sarker A, Gupta RD (2019) Designing antibody against highly conserved region of dengue envelope protein by in silico screening of scFv mutant library. PLoS One 14:e0209576. https:\/\/doi.org\/10.1371\/journal.pone.0209576","journal-title":"PLoS One"},{"key":"10541_CR45","doi-asserted-by":"publisher","first-page":"11800","DOI":"10.1128\/JVI.05237-11","volume":"85","author":"IA Rodenhuis-Zybert","year":"2011","unstructured":"Rodenhuis-Zybert IA, Moesker B, da Silva Voorham JM, van der Ende-Metselaar H, Diamond MS, Wilschut J, Smit JM (2011) A fusion-loop antibody enhances the infectious properties of immature flavivirus particles. J Virol 85:11800\u201311808. https:\/\/doi.org\/10.1128\/JVI.05237-11","journal-title":"J Virol"},{"key":"10541_CR46","doi-asserted-by":"publisher","unstructured":"Sarker A, Rathore AS, Gupta RD (2019) Evaluation of scFv protein recovery from E. coli by in vitro refolding and mild solubilization process. Microb Cell Factories 18:5. https:\/\/doi.org\/10.1186\/s12934-019-1053-9","DOI":"10.1186\/s12934-019-1053-9"},{"key":"10541_CR47","doi-asserted-by":"publisher","unstructured":"Smith SA, de Alwis AR, Kose N, Harris E,1 Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE (2013) The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain ii of the envelope protein. mBio 4. https:\/\/doi.org\/10.1128\/mBio.00873-13","DOI":"10.1128\/mBio.00873-13"},{"key":"10541_CR48","doi-asserted-by":"publisher","first-page":"9557","DOI":"10.1128\/JVI.00080-06","volume":"80","author":"K Stiasny","year":"2006","unstructured":"Stiasny K, Kiermayr S, Holzmann H, Heinz FX (2006) Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80:9557\u20139568. https:\/\/doi.org\/10.1128\/JVI.00080-06","journal-title":"J Virol"},{"key":"10541_CR49","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1128\/JVI.01087-10","volume":"84","author":"S Sukupolvi-Petty","year":"2010","unstructured":"Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS (2010) Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84:9227\u20139239. https:\/\/doi.org\/10.1128\/JVI.01087-10","journal-title":"J Virol"},{"key":"10541_CR50","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3181\/00379727-127-32768","volume":"127","author":"G Terres","year":"1968","unstructured":"Terres G, Morrison SL, Habicht GS (1968) A quantitative difference in the immune response between male and female mice. Exp Biol Med 127:664\u2013667. https:\/\/doi.org\/10.3181\/00379727-127-32768","journal-title":"Exp Biol Med"},{"key":"10541_CR51","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3390\/v3122374","volume":"3","author":"WMPB Wahala","year":"2011","unstructured":"Wahala WMPB, de Silva AM (2011) The human antibody response to dengue virus infection. Viruses 3:2374\u20132395. https:\/\/doi.org\/10.3390\/v3122374","journal-title":"Viruses"},{"key":"10541_CR52","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4049\/jimmunol.132.2.656","volume":"132","author":"Y Weinstein","year":"1984","unstructured":"Weinstein Y, Ran S, Segal S (1984) Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. J Immunol 132:656\u2013661","journal-title":"J Immunol"},{"key":"10541_CR53","doi-asserted-by":"publisher","first-page":"e0005584","DOI":"10.1371\/journal.pntd.0005584","volume":"11","author":"SS Whitehead","year":"2017","unstructured":"Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, Carmolli MP (2017) In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic insubjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis 11:e0005584. https:\/\/doi.org\/10.1371\/journal.pntd.0005584","journal-title":"PLoS Negl Trop Dis"},{"key":"10541_CR54","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.1128\/JVI.01874-13","volume":"87","author":"A Yamanaka","year":"2013","unstructured":"Yamanaka A, Kotaki T, Konishi E (2013) A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity. J Virol 87:12828\u201312837. https:\/\/doi.org\/10.1128\/JVI.01874-13","journal-title":"J Virol"},{"key":"10541_CR55","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.str.2004.06.019","volume":"12","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Zhang W, Ogata S, Clements D, Strauss JH, Baker TS, Kuhn RJ, Rossmann MG (2004) Conformational changes of the flavivirus e glycoprotein. Structure 12:1607\u20131618. https:\/\/doi.org\/10.1016\/j.str.2004.06.019","journal-title":"Structure"}],"container-title":["Applied Microbiology and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-020-10541-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00253-020-10541-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-020-10541-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:30:07Z","timestamp":1744176607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00253-020-10541-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10541"],"URL":"https:\/\/doi.org\/10.1007\/s00253-020-10541-y","relation":{},"ISSN":["0175-7598","1432-0614"],"issn-type":[{"type":"print","value":"0175-7598"},{"type":"electronic","value":"1432-0614"}],"subject":[],"published":{"date-parts":[[2020,3,30]]},"assertion":[{"value":"20 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the required ethical approvals have been taken before performing the experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the authors have given consent for the publication of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}}]}}